Investor Presentaiton

93 Investor presentation Full year 2022 Novo NordiskⓇ Large patient overlaps between diabetes, obesity, and CVD have guided the focused approach in CVD Population overlap between T2D, obesity and CVD ASCVD + HF ~425m people Atherosclerosis Focused approach in CVD Heart failure Inflammation-driven pathogenesis Heart failure with preserved ejection amyloid cardiomyopathy fraction Transthyretin (ATTR-CM) IL-6 Type 2 diabetes ~537m Obesity ~764m people people 之仆 CRP (HFPEF) > > > hsCRP as surrogate endpoint Improve outcomes Amyloid-depletion through antibody- mediated phagocytosis T2D: Type 2 diabetes, CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; HF: Heart failure; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein Sources: IDF Diabetes Atlas 2021, internal estimate based on European Cardiovascular Disease Statistics, 2017 edition, WHO obesity and overweight fact sheet, 9 June 2021

View entire presentation